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a b s t r a c t
This longitudinal study examines to what extent different depressive and anxiety disorders and clinical
characteristics are associated with subsequent weight change, while controlling for baseline weight,
sociodemographics, health status, psychotropic medication use and (un)healthy lifestyle factors. Data are
from a sample of 2447 respondents aged 18–65 years of the Netherlands Study of Depression and
Anxiety (NESDA). Baseline depressive disorders and anxiety disorders were determined with the
Composite International Diagnostic Interview (CIDI). Weight at baseline and after 2 years was measured
and analyzed as continuous change score (mean change in weight 1 kg) and in categories of sig-
niﬁcant weight loss (o1 S.D. weight change equaling o4 kg), weight maintenance and weight gain
(41 S.D., 46 kg). After full adjustment for covariates baseline comorbid anxiety and depressive
disorder and baseline Major Depressive Disorder (MDD) were associated with signiﬁcant 2-year weight
gain. Both current and remitted MDD at baseline and a baseline dysthymia, but none of the anxiety
disorders, were associated with signiﬁcant weight loss. This longitudinal study conﬁrms a U-curved link
between depression and weight change over 2 years. Furthermore, a dose–response effect of depression
severity on 2-year weight gain was found.
& 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Recent evidence has linked mental disorders and obesity – two
highly prevalent conditions – together. For instance, there is convin-
cing evidence that depression is associated with obesity and vice
versa (Atlantis and Baker, 2008; de Wit et al., 2010a, 2010b; Luppino
et al., 2010), although associations with underweight have also been
found (Seidell et al., 1999; Flegal et al., 2007). In line with this, de Wit
et al. (2009) and Zhao et al. (2009) found a U-curved association
between depression and Body Mass Index (BMI). Although it has
been less studied, there is also evidence for an association between
anxiety and obesity (Gariepy et al., 2010). Both weight gain and loss
are associated with elevated health risks (Must et al., 1999; Newman
et al., 2001; Field et al., 2001; Adams et al., 2006). Although weight
change can also be beneﬁcial for physical health outcomes
for instance when overweight or obese adults lose weight (Resnick
et al., 2000; Moore et al., 2005), the evidence for improvement on
psychological wellbeing is less convincing (Koster et al., 2010;
Jackson et al., 2014). Prospective studies in the adult population have
found that baseline depression and anxiety symptoms predicted
weight gain at follow-up (Forman-Hoffman et al., 2007; Brumpton
et al., 2013) and some recent studies found evidence for a bi-
directional association between depression and weight gain (Koster
et al., 2010; Singh et al., 2014). Patients with depressive and anxiety
disorders however, constitute a very heterogeneous population, it is
important to identify speciﬁc clinical factors (e.g. severity, subtype,
age of onset, chronicity) that are associated with weight change in
order to identify those who are most at risk. Recent studies found
evidence that especially persons with atypical features have an
elevated risk of weight gain (Levitan et al., 2012; Lasserre et al.,
2014), which underlines the importance of investigating clinical
characteristics. To further unravel the interplay between mental
disorders and such a U-curved association with weight change,
further longitudinal studies are necessary.
There is evidence that unhealthy lifestyles such as smoking,
alcohol consumption and being both socially and physically
inactive in adults is associated with having a depressive or anxiety
disorder as well as with abnormal Body Mass Index (BMI)(van
Gool et al., 2003; Berlin, 2008; Strine et al., 2008; de Wit et al.,
2010a, 2010b). Hence, people with mental disorders might change
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weight as a result of adopting an unhealthy lifestyle. Therefore
lifestyle behaviors are considered to be potential mediators in the
association between depression and anxiety disorders and obesity
(Friedman and Brownell, 1995). Nevertheless there are few studies
that consider the inﬂuence of such lifestyle factors when studying
the association between weight change and mental disorders.
Some recent cross-sectional and longitudinal studies suggest that
depressive and anxiety symptoms are associated with weight
independently from lifestyle factors (physical activity, smoking
and alcohol consumption) suggesting that there is no or a limited
inﬂuence of lifestyle factors (Zhao et al., 2009). Furthermore the
use of psychotropic medications, often prescribed for depressive
and anxiety disorders, might be an additional explanatory risk
factor for weight change (Virk et al., 2004; Demyttenaere and
Jaspers, 2008; Vieweg et al., 2008; Hasnain and Vieweg, 2013).
Underlying shared biological abnormalities such as inﬂammation,
leptin or HPA-axis dysregulations could further play a linking role
between mental health and weight change(Bjorntorp, 2001;
Bornstein et al., 2006; Pasco et al., 2008; Vreeburg et al., 2009;
Milaneschi et al., 2012).
There are previous studies that have investigated the associa-
tion between weight change and mental disorders in the adult
population, however most studies included adolescents (Haukkala
et al., 2001; Blaine, 2008; Liem et al., 2008; Luppino et al. 2010).
Few of the large-scale studies examining mental health and
weight associations have used well-deﬁned DSM-IV depressive
and anxiety diagnoses. Neither has the combined effect of depres-
sive and anxiety disorders or the inﬂuence of speciﬁc character-
istics of depressive and anxiety disorders (severity, subtype,
chronicity, age of onset) been examined in longitudinal associa-
tions with weight change.
Based on previous research we expect to ﬁnd an association
between depressive and anxiety disorders and weight gain
(Atlantis and Baker, 2008; de Wit et al., 2010a, 2010b; Luppino
et al., 2010; Gariepy et al., 2010; Koster et al., 2010; Brumpton
et al., 2013; Singh et al., 2014) and an association between
depressive disorders and weight loss (de Wit et al., 2009, Zhao
et al., 2009) over a 2-year period. When studying the association,
the extent to which speciﬁc clinical characteristics (severity,
subtype, chronicity, age of onset, and the use of psychotropic
medication) determine the association with subsequent weight
loss and gain will be examined and the role of sociodemographics
as well as (un)healthy lifestyle factors will be taking into account.
2. Methods
2.1. Study sample
Baseline and 2-year follow up data for this study were retrieved from the
Netherlands Study of Depression and Anxiety (NESDA), a longitudinal cohort study
designed to examine the long-term course of depressive and anxiety disorders. The
total sample at baseline consists of 2981 respondents aged 18–65 years, of whom
1979 (66.4%) were females and 97% had the Dutch nationality. At baseline, a total of
1701 (57.1%) subjects had a current (6-month recency) anxiety or depressive
disorder, 627 (21.0%) subjects had a remitted (lifetime but not current) anxiety or
depressive disorder and there were 652 (21.9%) controls without a lifetime
depressive or anxiety disorder. Respondents were recruited from the general
population, in general practices and in mental health organizations. Exclusion
criteria of the study were 1) a primary clinical diagnosis of a psychiatric disorder
not subject of NESDA, e.g. psychotic disorder, obsessive compulsive disorder, or
severe addiction disorder and 2) not being ﬂuent in Dutch language. A detailed
description of the baseline and 2-year follow up data collection procedures and
study design of NESDA has been reported elsewhere (Penninx et al., 2008; Lamers
et al., 2012).
The NESDA study protocol was approved centrally by the Ethical Review Committee
of the VU University Medical Center and by the local review boards of each participating
center. All respondents gave written informed consent. Both baseline and 2-year follow
up assessment included a 4-h interview and self-reported data on mental health
diagnoses, weight and height measures, lifestyle factors and sociodemographics at a
clinical site. For our longitudinal analyses we could not include a total of 534 persons of
the original sample because they either dropped out at the 2-year follow up measure
(non-response¼12.9%; N¼385), or had missing values on our main outcome variables
(N¼149). These non-responders were younger, less educated, from non-European
origin and more often suffering from depression, especially comorbid depressive and
anxiety disorder and higher symptom severity (Lamers et al., 2012).
2.2. Depressive and anxiety disorders and clinical characteristics
At baseline the DSM-IV Composite International Diagnostic interview (CIDI,
WHO version 2.1) was used to measure depressive and anxiety disorders: Major
Depressive Disorder (MDD), Dysthymia, Generalized Anxiety Disorder (GAD), Social
phobia, Panic disorder and Agoraphobia. The CIDI has proven to be a reliable and
valid instrument to assess depressive and anxiety disorders (Wittchen, 1994). All
respondents were assessed by specially trained clinical research staff at a clinical
site (Penninx et al., 2008; Lamers et al., 2012).
We used a 5-category indicator to classify depressive and anxiety disorder
status: healthy controls, remitted depressive or anxiety disorder (lifetime but not
present in past six months), depressive disorder only (in past six months), anxiety
disorder only (in past six months) and comorbid depressive and anxiety disorder
(in past six months). In order to examine the role of speciﬁc disorders we used a
3-category indicator for each type of assessed disorder: healthy controls, remitted
disorder (in lifetime but not present in past six months) and current disorder (in
past six months).
Additionally considered clinical characteristics were severity, subtype, age of
onset and duration. Severity of depressive symptoms was measured using the
28-item Inventory of Depressive Symptomatology (IDS) to obtain a score between
0 and 84. We used continuous as well as categorized severity scores of the IDS:
none (0–13), mild (14–25), moderate (26–38), severe (39–48) very severe (49–84)
(Rush et al., 1996, 2003). Severity of anxiety was measured with the 21-item Beck
Anxiety Inventory (BAI) (Beck et al., 1988). The presence of symptoms of atypical
depression and melancholic depression were assessed with the IDS as done before
(van Reedt Dortland et al., 2010). Atypical depression is characterized by mood
reactivity and at least 2 symptoms of vegetative reversal (including overeating,
oversleeping, severe fatigue or leaden paralysis, and a history of rejection
sensitivity) (Stewart and Thase, 2007). Melancholic depression is characterized by
lack of mood reactivity or loss of pleasure and at least 3 symptoms of distinct mood
quality (including mood worse in the morning, early morning awakening, psycho-
motor retardation or agitation, anorexia/weight loss and guilt feelings) (Kahn et al.,
2008). Age of onset of the disorder was assessed with the CIDI interview. The Life
Chart interview (Lyketsos et al., 1994) was used to determine chronicity of the
disorders in terms of the percentage of time in the 4 years prior to baseline that
respondents had depressive and/or anxiety symptoms. Psychotropic medication
use was based on drug container inspection of drugs used in the past month, and
classiﬁed according to the WHO ATC classiﬁcation.
Antidepressants were categorized as selective serotonin reuptake inhibitors (SSRIs)
(ATC code N06AB), tricyclic antidepressants (TCAs) (ATC code N06AA), and other
antidepressants (ATC codes N06AF and N06AX), anti-anxiety medication was categor-
ized as Benzodiazepine use (no use/ infrequent use/ frequent use) (ACT code N05BA).
2.3. Weight assessment
At baseline and 2-year follow up, weight and height were measured by trained
clinical research staff at a clinical site (Penninx et al., 2008; Lamers et al., 2012).
Because psychopathology is associated with both high and low BMI the possibility
exists of a U-shaped association between psychopathology and weight change (de
Wit et al., 2009). Therefore we used a three category indicator for weight change
(weight loss, weight maintenance and weight gain). Respondents were categorized
by either clinically signiﬁcant weight gain or weight loss when they changed at
least 1 standard deviation (S.D.¼5 kg) weight between baseline and follow up
measure, calculated from the mean weight change (Mean¼1 kg weight gain) of the
total sample (Newman et al., 2001; Stevens et al., 2006). We conducted additional
analyses using a continuous indicator of weight change by calculating 2-year follow
up weight minus baseline weight in order to obtain further conﬁrmation of speciﬁc
ﬁndings. A positive score indicates total kilograms weight gain and a negative score
indicates total kilograms weight loss of a person.
2.4. Covariates
Baseline covariates included gender, age (continuous), years of education
(continuous) and baseline height and weight. Baseline health status was measured
by number of chronic diseases for which one receives medical treatment including
lung disease, osteoarthritis, cancer, gastrointestinal disease, liver disease, epilepsy,
thyroid disease. Lifestyle indicators included smoking status (never, current,
former), alcohol intake (amount of alcoholic drinks a day), physical activity
(continuous) and social activity (continuous). Physical activity was measured with
the International Physical Activity Questionnaire (IPAQ), which has proven to be a
valid and reliable instrument to measure physical activity (Craig et al., 2003;
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Hagstromer et al., 2006). The overall energy expenditure was expressed in
Metabolic Equivalent Total (MET)-units by calculating activity x frequency of the
activity x MET intensity (Ainsworth et al., 1993; Craig et al., 2003). The total MET-
minutes per week/1000 were used as a continuous indicator for physical activity.
Furthermore we controlled for social activity because previous research has found
social activity to be related to both weight and psychopathology (de Wit et al.,
2010a, 2010b). Social activity was assessed by self-report. A continuous indicator
was calculated by the frequency respondents visited a total of four social activities,
1) cultural events (theater, cinema, museum); 2) trips to nature or amusement
parks or interesting buildings; 3) visiting a bar, restaurant or dancing; 4) attending
an activity or meeting at a club or association.
2.5. Statistical analyses
Statistical analyses were conducted using SPSS 14.0 (Inc., Chicago, Illinois, USA).
We described sociodemographics, lifestyle, antidepressant use and weight mea-
sures across depressive and anxiety status using χ² and ANOVA analyses. Multi-
nomial regression analyses were adjusted in two steps 1) for sociodemographics,
baseline height and weight(Forman-Hoffman et al., 2007; Koster et al., 2010;
Lasserre et al., 2014) and 2) additionally for baseline health, psychotropic medica-
tion use and lifestyle indicators to examine the association between psychiatric
status and weight change categories (weight loss and weight gain, with weight
maintenance as reference). Adjusted linear regression analyses were conducted to
examine the association between psychopathology and continuous 2-year weight
change to conﬁrm speciﬁc ﬁndings based on the categorical weight indicators. For
both multinomial regression and linear regression analyses two separate models
were tested. The ﬁrst model examined the association with a 5-category indicator
of depressive and anxiety status (healthy controls, remitted depressive and/or
anxiety status, current depressive disorder only, current anxiety disorder only and
current comorbid depressive and anxiety disorder). The second model examined
simultaneously the association with individual DSM-IV depressive and anxiety
disorders: MDD, Dysthymia, GAD, Social phobia, Panic disorder and Agoraphobia,
specifying each speciﬁc disorder into: no disorder, remitted disorder or current
disorder. We tested the interaction between sex and depression and anxiety status
and weight loss and gain using multinomial logistic regression analysis, which
appeared to be non-signiﬁcant (p¼0.956 and p¼0.825 respectively).
In the subsample of respondents with a current depressive and/or anxiety disorder
at baseline multinomial logistic regression analyses adjusted for covariates were used
to examine the separate associations between weight change and clinical character-
istics (severity, subtype, chronicity, age of onset and use of antidepressant medication).
Subsequently, to test the independent association of clinical characteristics with
weight change, one ﬁnal multinomial regression analysis adjusted for covariates was
conducted to test all clinical characteristics simultaneously.
3. Results
At baseline, 321 (13.0%) of the 2447 respondents had a current
depressive disorder only, 447 (18.3%) a current anxiety disorder
only, 562 (22.9%) a comorbid depressive and anxiety disorder, 548
(22.4%) had a remitted depressive and/or anxiety disorder and 569
(23.3%) were healthy controls. The mean age of the respondents
included in these analyses was 42.3 years (S.D.¼13.1) at baseline
and 65.7% were female.
Between baseline and 2-year follow up the meanweight change of
the total sample was þ1 kg weight gain, with a standard deviation of
5 kg. We categorized 317 (13.0%) persons as weight gainers (Z6 kg)
and 257 (10.5%) persons as weight losers (Z4 kg). Those persons who
changed weight were more often persons with psychopathology
(po0.001). Furthermore respondents with current and remitted
depressive and/or anxiety disorders in this sample were more often
female, older, lower educated, socially inactive and were more likely to
be a smoker (Table 1).
3.1. Psychopathology and weight change
Adjusted multinomial regression analyses were conducted to
examine whether depressive and anxiety disorders at baseline
were associated with both weight loss and weight gain (weight
maintenance as reference) at 2-year follow-up while controlling
for baseline height and weight, sex, age and years of education in
the ﬁrst step and additionally controlling for alcohol use, smoking,
antidepressant use, benzodiazepine use, number of chronic
diseases, social activity and physical activity in the second step
(Table 2). We did not ﬁnd any signiﬁcant associations between
mental disorder status (at baseline) and weight loss. Having
current MDD (OR¼1.48; 95% CI: 1.00–2.20), a remitted MDD
(OR¼1.53; 95% CI: 1.05–2.24) or current dysthymia (OR¼1.85;
95%CI: 1.14–3.00) were signiﬁcantly associated with weight loss
after adjusting for all covariates (step 2). Examining the contin-
uous indicator for weight loss and the association with mental
disorders gave similar results: persons with current dysthymia
(β¼0.07; po0.001) showed signiﬁcantly more weight loss over
a 2-year period.
Having a current comorbid depressive and anxiety disorder at
baseline was signiﬁcantly associated with weight gain (OR¼2.06;
95% CI: 1.45–2.92), also after further adjustment for all covariates
(OR¼1.70; 95% CI: 1.16–2.50). Examining speciﬁc depressive or
anxiety diagnoses at baseline, we found that weight gain was
signiﬁcantly associated with having current MDD (OR¼1.66; 95%
CI: 1.30–2.46). Furthermore, agoraphobia had elevated odds for
weight gain after full adjustment as well, however this was not
signiﬁcant (OR¼1.32; 95% CI: 0.80–2.18). Examining the contin-
uous indicator for weight gain and mental disorders gave similar
results: persons with comorbid depressive and anxiety disorder
(β¼0.10; po0.001) and current MDD (β¼0.09; po0.05) and
current panic disorder (β¼0.05; po0.05) showed more weight
gain over a 2-year period.
3.2. Weight change and speciﬁc characteristics of psychopathology
To test whether speciﬁc clinical characteristics were associated
with weight change we conducted multinomial regression analyses
in the 1330 persons with a current depressive and/or anxiety
disorder. Adjusted analyses per speciﬁc clinical characteristic are
presented in Table 3. Weight loss was not associated with severity of
anxiety, atypical and melancholic features, antidepressant medica-
tions, benzodiazepine use, and chronicity of symptoms or with age of
onset. Severity of depression and severity of anxiety were found to be
signiﬁcantly associated with weight gain (OR per score
increase¼1.04; 95% CI: 1.03–1.06 and OR¼1.03; 95% CI: 1.02–1.05
respectively). Also more melancholic features (OR¼2.24; 95% CI:
1.43–3.52), more atypical features (OR¼1.50; 95% CI: 1.02–2.21),
using benzodiazepine (infrequent use: OR¼1.85, 95% CI: 1.17–2.92,
frequent use: OR¼2.06, 95% CI: 1.23–3.27), and using SSRIs
(OR¼1.57; 95% CI: 1.11–2.23) were associated with weight gain.
Finally all clinical characteristics were examined in one multi-
variable model simultaneously which in order to examine inde-
pendent effects. Severity of depression was the only clinical
characteristic that remained a signiﬁcant predictor for weight gain
(OR per score increase¼1.05; 95% CI: 1.02–1.07). Benzodiazepine
use had elevated odds for weight gain as well, however this was
not signiﬁcant (infrequent use: OR¼1.58; 95% CI: 0.98–2.56;
frequent use: OR¼1.53, 95% CI: 0.93–2.52). Fig. 1 shows the
division of the relative weight change (RWC¼(baseline weight-
follow up weight)/baseline weight) categories across severity of
depressive symptom categories. In line with our previous analyses
we categorized a person with either weight loss or weight gain
when the relative weight change was at least 1 standard deviation
from the mean.
4. Discussion
Results of this longitudinal study showed that persons with a
current comorbid depressive and anxiety disorder and a current
MDD at baseline are more likely to experience signiﬁcant wei-
ght gain over a 2-year period. Persons having a current MDD,
a remitted MDD or current dysthymia at baseline more often
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experienced weight loss. These associations were independent of
sociodemographics, health status, and psychotropic medication
use and (un) healthy lifestyle. These ﬁndings provide longitudinal
conﬁrmation of the earlier reported U-curved association between
depressive disorders and weight change (Haukkala et al., 2001; de
Wit et al., 2009). A dose–response association existed with more
severe symptoms of depression being associated with more
weight gain over a 2-year period.
This study showed that persons with a comorbid anxiety and
depressive disorder had a 70% increased chance of gaining
signiﬁcant weight over a 2 year period. This was expected since
persons with comorbid disorders have more severe symptoms
(Lamers et al., 2011). In line with this, we found that depression
severity was a predictor of weight gain. Increased appetite while
experiencing stress is a feature of the atypical subtype. Contrary to
previous studies we did not ﬁnd an effect of atypical features on
weight gain (Levitan et al., 2012; Lasserre et al., 2014). The
observed effects in our study seemed mainly to be driven by
overall severity of depression, but not very different for speciﬁc
symptom proﬁles. (Angst et al., 2007; Lamers et al., 2010). In the
present study we use the IDS for both subtype classiﬁcation as
well as severity classiﬁcation, so it might as well be possible that
subtype is overruled by severity. The high correlations between
clinical characteristics in our study hinder to distinguish between
the individual effects.
Furthermore we found evidence that persons with current
MDD at baseline had a 66% increased chance of gaining 6 kg or
more over a 2-year period compared to healthy controls. Persons
with current agoraphobia had a 32% increased chance of gaining
6 kg or more, however this result was not signiﬁcant. However this
might be due to the lack of power since only 152 (6.2%) persons in
our study had a current agoraphobia at baseline. These ﬁndings
support the results of recent meta-analyses that depressive and
anxiety disorders at baseline lead to obesity at follow-up (Blaine,
2008; Gariepy et al., 2010; Luppino et al., 2010). Such a conse-
quence could ultimately also contribute to the observed increased
mortality and morbidity (e.g. cardiovascular disease and diabetes)
among persons with depressive and anxiety disorders (Cuijpers
and Smit, 2002; Nicholson et al., 2006; van Dooren et al., 2013). It
has been hypothesized that depression and anxiety lead to weight
gain through the adoption of unhealthy lifestyles in people with
mental disorders such as increased food intake, smoking, alcohol
consumption and decreased activity (Blaine, 2008; Faith et al.,
2002; Konttinen et al., 2010). However in our study we found
evidence for an association between mental disorders and weight
gain independent of smoking, alcohol consumption, physical
activity and social activity, which was in line with recent pro-
spective studies that adjusted for lifestyle (Brumpton et al., 2013;
Singh et al., 2014; Lasserre et al., 2014). The use of psychotropic
medication has been suggested as a confounding factor in the
association between psychopathology and weight change since
medication use has shown to interact with mechanisms regulating
food intake and appetite (Virk et al., 2004; Demyttenaere and
Jaspers, 2008; Papakostas, 2008; Vieweg et al., 2008; Hasnain and
Vieweg, 2013). Initially we found in a subsample of our study with
persons having a current depressive and anxiety disorders that
Table 1
Description of baseline characteristics and weight (change) across depression and anxiety status groups (N¼2447)a.
Value N % Controls
(N¼569)
Remitted
(N¼548)
Depression only
(N¼321)
Anxiety only
(N¼447)
Comorbid anxiety and
depression (N¼562)
P
Demographics
Gender Female 1608 65.7 59.4 71.4 63.2 67.1 66.9 o0.001
Male 839 34.3 40.6 28.6 36.7 32.9 33.1
Age(years) Mean (S.D.) 42.3(13.1) 41.2(14.6) 44.6(13.0) 41.3(12.4) 41.9(12.6) 42.0(12.1) o0.001
Level of education High 903 36.9 45.5 42.5 37.4 33.1 25.4 o0.001
Intermediate 1401 57.3 51.0 51.8 57.6 61.1 65.7
Low 143 5.8 3.5 5.7 5.0 5.8 8.9
Health status Mean(S.D.) 0.6(0.9) 0.5(0.8) 0.6(0.8) 0.6(0.9) 0.7(0.9) 0.6(0.9) 0.093
IDS Mean(S.D.) 20.5(13.8) 8.3(7.2) 13.8(8.6) 27.1(11.0) 22.0(9.8) 34.4(11.9) o0.001
BAI Mean(S.D.) 11.4(10.1) 3.9(4.7) 7.0(6.3) 11.4(7.9) 14.7(9.3) 20.4(10.6) o0.001
Age of Onset(year) Mean(S.D.) 22.7(12.9) 32.2(12.6) 26.1(13.0) 26.0(13.1) 19.7(11.8) 19.7(12.1) o0.001
Duration of
symptoms(months)
Mean(S.D.) 34.4(36.4) 6.9(17.7) 18.4(27.3) 36.5(29.6) 54.9(38.7) 60.7(33.8) o0.001
Benzodiazepine use No 2087 85.3 97.4 91.2 84.4 81.9 70.5 o0.001
Unfrequent 193 7.9 2.3 6.6 7.2 10.7 13.0
Frequent 167 6.8 0.4 2.2 8.4 7.4 6.8
Antidepressant use No 1840 75.5 99.1 86.4 64.2 70.9 50.8 o0.001
SSRI 402 16.5 0.7 10.8 23.7 18.3 32.6
TCA 65 2.7 0.2 1.6 2.5 4.3 5.0
Other 130 5.4 0.0 1.1 9.5 6.5 11.6
Daily alcohol use
(unit's)
Mean(S.D.) 1.0 (1.4) 1.1(1.3) 1.0(1.3) 1.0(1.5) 1.0(1.5) 1.0(1.6) 0.853
Smoking status No, never 713 29.1 37.6 26.6 26.8 23.4 29.0 o0.001
No, stopped 851 34.8 35.5 40.1 33.3 36.2 28.5
Yes, current 883 36.1 26.9 33.2 39.9 40.5 42.5
Social activity Mean (S.D.) 9.9(3.2) 10.8(2.9) 10.3(3.1) 9.6(3.2) 9.9(3.2) 8.7(3.0) o0.001
Physical activity
(MET's)
Mean (S.D.) 3.7(3.1) 3.9(3.1) 3.9(2.9) 3.5(3.2) 3.7(3.0) 3.5(3.1) 0.185
Height Mean(S.D.) 172.9(9.2) 173.9(9.5) 171.9(8.7) 173.7(9.2) 173.0(9.2) 172.9(9.2) 0.002
Weight measures(kg)
Baseline weight Mean(S.D.) 76.5(16.6) 75.8(16.1) 76.6(15.9) 77.4(17.4) 75.5(16.5) 77.5(17.5) 0.222
Follow up weight Mean (S.D.) 77.4(16.6) 76.6(16.0) 77.0(15.9) 78.43(17.4) 76.3(16.6) 79.0(17.3) 0.042
Weight changeb Loss 257 10.5 8.9 11.5 11.2 8.1 12.6 o0.001
Equal 1873 76.5 80.1 79.9 74.1 80.8 67.6
Gain 317 13.0 10.9 8.6 14.6 11.2 19.8
a Based on Pearson χ² and ANOVA analyses (unadjusted).
b Based on Z1 S.D. (¼5 kg) substantial weight change.
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SSRI users as well as benzodiazepine users compared to non-users
were more likely to gain weight. However, the found effects for
SSRI use seemed to be mainly driven by the severity of the
depressive symptoms. Surprisingly, the effect of benzodiazepine
use on weight gain remained borderline signiﬁcant after full
adjustment, which is conﬂicting with previous research which
found that benzodiazepine use was weight neutral (Vieweg et al.,
2008; Hasnain and Vieweg, 2013). Other explaining mechanisms
for the association between mental disorders and subsequent
weight increase are physiological abnormalities found in
depressed persons such as increased inﬂammation, and long-
term disturbances of the HPA-axis. These abnormalities also form
risk factors for obesity (Bjorntorp, 2001; Bornstein et al., 2006;
Vreeburg et al., 2009). Further research is needed to examine the
Table 2
Multivariate association between depressive and anxiety disorders and weight change (N¼2447)a.
N % Weight loss adjusteda Weight loss fully adjustedb Weight gain adjusteda Weight gain fully adjustedb
OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
Model 1: Mental disorders in general
Controls 569 23.3 ref ref ref ref
Remitted disorder 548 22.4 1.20 0.80–1.81 0.372 1.23 0.81–1.87 0.331 0.85 0.56–1.27 0.434 0.83 0.55–1.25 0.366
Current depressive disorder 321 13.1 1.22 0.76–1.96 0.408 1.32 0.81–2.18 0.268 1.41 0.93–2.14 0.105 1.21 0.78–1.87 0.387
Current. anxiety disorder 447 18.3 0.84 0.53–1.34 0.475 0.93 0.56–1.51 0.778 1.02 0.68–1.52 0.936 0.90 0.60–1.37 0.633
Current. comorbid disorder 569 23.0 1.43 0.96–2.14 0.082 1.45 0.92–2.29 0.110 2.06 1.45–2.92 o0.001 1.70 1.16–2.50 0.007
Model 2: Speciﬁc disorders
Major Depressive No 905 37.1 ref ref ref ref
Disorder Remitted 687 28.2 1.54 1.06–2.23 0.023 1.53 1.05–2.24 0.027 1.15 0.80–1.64 0.458 1.11 0.78–1.65 0.557
Current 845 34.7 1.41 0.97–2.06 0.070 1.48 1.00–2.20 0.051 1.81 1.31–2.48 o0.001 1.66 1.30–2.46 0.002
Dysthemia No 1923 78.9 ref ref ref ref
Remitted 302 12.4 1.03 0.66–1.60 0.914 1.05 0.67–1.65 0.830 1.17 0.78–1.76 0.446 1.12 0.75–1.70 0.566
Current 212 8.7 2.02 1.28–3.19 o0.001 1.85 1.14–3.00 0.012 1.46 0.96–2.22 0.078 1.33 0.86–2.21 0.197
Generalized No 1827 75.0 ref ref ref ref
Anxiety Disorder Remitted 271 11.1 0.91 0.58–1.42 0.669 0.90 0.57–1.43 0.664 0.73 0.47–1.15 0.178 0.77 0.49–1.21 0.258
Current 339 13.9 0.93 0.61–1.43 0.750 0.94 0.60–1.47 0.782 1.00 0.70–1.43 0.997 0.99 0.69–1.42 0.958
Social Phobia No 1717 70.5 ref ref ref ref
Remitted 203 8.3 0.83 0.49–1.40 0.487 0.89 0.52–1.51 0.661 0.79 0.48–1.31 0.364 0.82 0.49–1.37 0.450
Current 517 21.2 1.03 0.72–1.47 0.871 1.06 0.73–1.53 0.775 0.80 0.58–1.10 0.162 0.78 0.57–1.08 0.135
Panic disorder No 1753 71.9 ref ref ref ref
Remitted 179 7.3 0.82 0.48–1.39 0.458 0.86 0.50–1.47 0.576 0.62 0.35–1.13 0.123 0.63 0.33–1.09 0.095
Current 505 20.7 0.80 0.54–1.17 0.246 0.84 0.56–1.26 0.391 1.42 1.04–1.94 0.027 1.31 0.95–1.81 0.094
Agoraphobia. No 2201 90.3 ref ref ref ref
Remitted 84 3.4 1.14 0.57–2.28 0.722 1.10 0.54–2.26 0.793 1.19 0.59–2.41 0.633 1.19 0.58–2.42 0.633
Current 152 6.2 1.01 0.58–1.77 0.970 1.04 0.58–1.86 0.892 1.40 0.86–2.30 0.179 1.32 0.80–2.18 0.274
cAnalyses adjusted for psychopathology, baseline weight, baseline height, sex, age, years of education, alcohol use, smoking, antidepressant use, benzodiazepine use, number
of chronic diseases, social activity and physical activity.
a Based on adjusted multinomial logistic regression analyses. Categories based on Z1 S.D. (¼5.0 kg) substantial weight change and weight maintenance as reference
category.
b Analyses adjusted for baseline weight, baseline height, sex, age and years of education.
Table 3
Multivariate associations between characteristics of metal disorders and weight change in the subsample of persons with a current depressive or anxiety disorder
(N¼1330)a,b.
Characteristics of mental disorders Weight lossa Weight lossb Weight gaina Weight gainb
OR 95%CI P OR 95%CI P OR 95%CI P OR 95%CI P
Depression severity 1.02 1.00–1.03 0.117 1.02 0.99–1.05 0.133 1.04 1.03–1.06 o0.001 1.05 1.02–1.07 o0.001
Severity of melancholic features 0.90 0.546–1.76 0.762 0.60 0.28–1.31 0.199 2.24 1.43–3.51 o0.001 1.00 0.58–1.71 0.996
Severity of atypical features 1.54 0.98–2.43 0.06 1.23 0.72–2.12 0.453 1.50 1.02–2.21 0.040 0.79 0.50–1.24 0.302
Anxiety severity 1.01 0.99–1.02 0.604 0.99 0.97–1.02 0.478 1.03 1.02–1.05 o0.001 1.00 0.98–1.02 0.952
Chronicity of symptoms 1.00 1.00–1.01 0.382 1.00 1.00–1.01 0.460 1.00 1.00–1.01 0.834 1.00 0.99–1.00 0.259
Age of onset 1.00 0.99–1.02 0.760 1.01 0.99–1.02 0.567 1.00 1.00–1.00 0.565 1.01 0.99–1.02 0.476
Antidepressant use none ref ref ref ref
SSRI 0.85 0.55–1.39 0.574 0.88 0.54–1.44 0.606 1.57 1.11–2.23 0.010 1.20 0.82–1.74 0.349
TCA 1.44 0.64–3.23 0.371 1.39 0.60–3.21 0.437 0.90 0.36–2.25 0.824 0.75 0.30–1.95 0.564
Other 0.88 0.42–1.68 0.637 0.88 0.43–1.76 0.708 1.60 0.96–2.68 0.073 1.21 0.70–2.10 0.487
Benzodiazepine use
No ref ref ref ref
Unfrequent 0.99 0.54–1.83 0.984 1.09 0.59–2.03 0.776 1.85 1.17–2.92 0.008 1.58 0.98–2.56 0.063
Frequent 0.87 0.48–1.61 0.665 0.77 0.40–1.50 0.447 2.06 1.23–3.27 0.002 1.53 0.93–2.52 0.098
Based onZ1 S.D. (¼5.0 kg) substantial weight change.
a Based on multinomial logistic regression analyses, baseline height, weight, sex, age, years of education smoking status, alcohol use, social activity, physical activity and
number of chronic diseases.
b Based on multinomial logistic regression analyses, baseline height, weight, sex, age, years of education, smoking status, alcohol use, social activity, physical activity,
number of chronic diseases and all other characteristics of mental disorders.
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inﬂuencing role of pathophysiological factors in the link between
mental disorders and weight change.
Persons with a current MDD, as well as persons with current
dysthymia were more likely to lose 4 kg's or more over a 2-year
period independent of lifestyle and health status. These ﬁndings
conﬁrm our hypothesis of a U-shaped association between weight
change and depressive disorders (Forman-Hoffman et al., 2007 de
Wit et al., 2009, Zhao et al., 2009). Nevertheless, further studies
are needed to conﬁrm the association between MDD and dysthy-
mia and weight loss.
Increased and decreased appetite are core features of depres-
sion diagnosis which is an explanatory factor of weight change in
depressed persons (Privitera et al., 2013). In addition, previous
research reported an association between food insufﬁciency and
dysthymia, however this was not found for MDD (Alaimo et al.,
2002). Further research should examine the mediating inﬂuence of
eating behaviors on the association between anxiety and depres-
sive disorders and weight change (Torres and Nowson, 2007).
Persons with remitted MDD had a 53% increased chance of
losing44 kg over a 2-year period. It is likely that the persons who
gain weight when having a current MDD episode may be the same
persons who also lose weight when the MDD is remitted because of a
healthier lifestyle or restored biological dysfunction. In addition to this
it must be noted that weight change is not an indicator of psycholo-
gical distress in all cases(Forman-Hoffman et al., 2007; Koster et al.,
2010; Jackson et al., 2014). In some cases it can even be an indicator of
well-being. For instance both persons who were underweight before
and gain weight and persons who were overweight and lose weight,
weight change is likely to have positive effect on well-being (Resnick
et al., 2000; Moore et al., 2005).
Consequently, this might suggest that MDD patients when in
remission lose some of the weight that they gained when
symptomatic. The mechanisms that cause weight loss in remitted
depressed persons, e.g. healthier food intake or restored biological
dysfunction, require more longitudinal research. The observed
U-curved association between depression severity and weight
change suggests that there are diverse mechanisms underlying
the association between depression and unhealthy weight, one
pathway leading to weight gain and one leading to weight loss.
A limitation of this study was the relatively short follow-up period
of two years. Previous research has demonstrated stronger associa-
tions between obesity and depression after a follow-up period of 10
years (Luppino et al., 2010). It must be noted that age of onset is
based on retrospective reports which have a risk of an incorrect recall
(Simon and VonKorff, 1995; Kessler et al., 2007). Furthermore,
previous studies provided evidence for a bi-directional association
between mental disorders and weight change (Koster et al., 2010;
Singh et al., 2014). However, in our study we were not able to
investigate the effect of weight change on the onset of depressive
and anxiety disorders since data on weight status previous to
baseline measures were not available. An additional limitation is
the lack of eating behaviour information which did not allow us to
examine underlying nutritional variations as explaining mechanisms
in the observed associations. When examining speciﬁc disorders we
adjusted for comorbidity and therefore were not able to look at the
joint effects of speciﬁc disorders. Future research has to focus on the
effect of comorbid depressive and anxiety diagnoses on weight gain.
There was a drop out of 12.9% at the 2 years follow up assessment.
However these persons suffered from more severe symptoms we do
not expect this to affect the results (Lamers et al., 2012).
The strength of this study is the use of a large study sample and
detailed assessment in which we were able to separate and
compare the impact of DSM-IV based depressive and anxiety
diagnoses on weight change. Weight and height were measured
by well-trained research staffs which limit the possibility of bias
that often occurs with self-report (Gorber et al., 2007). Further-
more we were able to examine speciﬁc characteristics of depres-
sive and anxiety disorders and examine the role of various
sociodemographic and lifestyle factors.
In sum, this study gives longitudinal evidence for a U-shaped
association between depressive disorders and weight change
independent of lifestyle, health status, psychotropic medication
use and socio-demographic factors. A depressive disorder is a
possible risk factor for gaining weight as well as losing weight,
which are both linked to increased mortality. These two different
pathways suggest that diverse mechanisms can be activated in
depressed persons, one leading to weight gain and another leading
to weight loss. Future research should focus on exploring which
differential mechanisms underlie these diverse patterns. Our
results imply that it is important for clinicians to monitor the
weight changes when a person is suffering from depression in
order to prevent an unhealthy weight.
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